Cytokinetics, Incorporated (CYTK)
After hours:
| Previous Close | 59.53 |
| Open | 59.59 |
| Bid | 60.50 x 200 |
| Ask | 60.62 x 400 |
| Day's Range | 59.33 - 61.40 |
| 52 Week Range | 25.98 - 110.25 |
| Volume | |
| Avg. Volume | 1,929,620 |
| Market Cap | 6.354B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.40 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 92.06 |
GlobeNewswireCytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) today, May 17th, 2024 at the Mission Bay Conference Center in San Francisco. “We are proud to convene the CLIMB Research Symposium, a unique forum for the muscle biology community, including academic researchers and students, to engage in scientific discussion an
- GlobeNewswire
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at the European Society of Cardiology Congress 2024, taking place in London, UK from August 30, 2024 – September 2, 2024. Title: Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR SubstudyPresenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy C
Investor's Business DailyCytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug
Cytokinetics said Monday its drug "significantly" improved exercise capacity in HCM patients. On Tuesday, Cytokinetics stock reversed higher.
